Companies Intra-Cellular Therapies
Intra-Cellular Therapies (ITCI): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Intra-Cellular Therapies no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers29th pct.Of 17 peer CEOs
CEO pay, last three years
- $7,245,943FY2021
- $9,232,857FY2022
- $10,086,413FY2023
CEO total pay was $10,086,413 in fiscal 2023, up from $9,232,857 in fiscal 2022.
FY2023: salary $891,653 · bonus $1,426,645 · stock awards $7,749,984 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Intra-Cellular Therapies in fiscal 2023?
As disclosed, Sharon Mates (Chairman and Chief Executive Officer) was the highest-paid executive at Intra-Cellular Therapies in fiscal 2023, with total compensation of $10,086,413.
How does Intra-Cellular Therapies's chief executive pay compare to its disclosed peer group?
As disclosed, Sharon Mates's total compensation ranked at the 29th percentile of Intra-Cellular Therapies's disclosed peer group.
What is Intra-Cellular Therapies's CEO-to-median employee pay ratio?
As disclosed, Intra-Cellular Therapies's CEO-to-median employee pay ratio was 46:1.
How did shareholders vote on Intra-Cellular Therapies's executive compensation?
As disclosed, 91.47% of shareholders supported Intra-Cellular Therapies's executive compensation in the latest say-on-pay vote.
How much does Intra-Cellular Therapies spend in total on board compensation for fiscal 2023?
As disclosed, Intra-Cellular Therapies reported total board compensation of $712,788 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sharon Mates | $891,653 | $1,426,645 | $7,749,984 | $0 | $0 | $0 | $18,131 | $10,086,413 |
| Chairman and Chief Executive Officer | ||||||||
| Mark Neumann | 586,471 | 439,853 | 2,499,998 | 0 | 0 | 0 | 16,706 | 3,543,028 |
| Executive Vice President, Chief Commercial Officer | ||||||||
| Michael Halstead | 578,673 | 434,005 | 2,499,998 | 0 | 0 | 0 | 13,557 | 3,526,233 |
| President | ||||||||
| Suresh Durgam | 569,784 | 427,338 | 2,499,998 | 0 | 0 | 0 | 14,055 | 3,511,175 |
| Executive Vice President, Chief Medical Officer | ||||||||
| Lawrence Hineline | 523,744 | 314,246 | 2,499,998 | 0 | 0 | 0 | 23,122 | 3,361,110 |
| Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Sharon Mates | $10,086,413 | $9,232,857 | $7,245,943 | ↑ +853,556 |
| Mark Neumann | 3,543,028 | 3,498,329 | 2,757,086 | ↑ +44,699 |
| Michael Halstead | 3,526,233 | 3,483,622 | 2,827,775 | ↑ +42,611 |
| Suresh Durgam | 3,511,175 | 3,461,807 | 2,775,676 | ↑ +49,368 |
| Lawrence Hineline | 3,361,110 | 2,720,478 | 2,440,992 | ↑ +640,632 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our overall compensation program is structured to attract, motivate and retain highly qualified executive officers by paying them competitively, consistent with our success and their contribution to that success. Compensation is aligned with our performance on both a short-term and long-term basis, linked to results intended to create value for stockholders, and assists in attracting and retaining key executives critical to our long-term success.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Suresh Durgam | PSU | 2023-03-06 | 6,567 | 13,134 | — | 16,416 | $625,047 |
| Suresh Durgam | RSU | 2023-03-06 | — | — | 39,398 | — | 1,874,951 |
| Mark Neumann | RSU | 2023-03-06 | — | — | 39,398 | — | 1,874,951 |
| Lawrence Hineline | RSU | 2023-03-06 | — | — | 39,398 | — | 1,874,951 |
| Michael Halstead | RSU | 2023-03-06 | — | — | 39,398 | — | 1,874,951 |
| Sharon Mates | RSU | 2023-03-06 | — | — | 122,137 | — | 5,812,500 |
| Mark Neumann | PSU | 2023-03-06 | 6,567 | 13,134 | — | 16,416 | 625,047 |
| Lawrence Hineline | PSU | 2023-03-06 | 6,567 | 13,134 | — | 16,416 | 625,047 |
| Michael Halstead | PSU | 2023-03-06 | 6,567 | 13,134 | — | 16,416 | 625,047 |
| Sharon Mates | PSU | 2023-03-06 | 20,356 | 40,712 | — | 50,890 | 1,937,484 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Suresh Durgam | $1,874,951 | $625,047 | $0 | 25.0% |
| Mark Neumann | 1,874,951 | 625,047 | 0 | 25.0% |
| Lawrence Hineline | 1,874,951 | 625,047 | 0 | 25.0% |
| Michael Halstead | 1,874,951 | 625,047 | 0 | 25.0% |
| Sharon Mates | 5,812,500 | 1,937,484 | 0 | 25.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lawrence Hineline | Option | 5,882 | 36.89 | — |
| Michael Halstead | Option | 6,238 | 36.89 | — |
| Suresh Durgam | Option | 6,238 | 36.89 | — |
| Mark Neumann | Option | 6,238 | 36.89 | — |
| Lawrence Hineline | PSU | 6,698 | — | 479,711 |
| Lawrence Hineline | RSU | 7,455 | — | 533,927 |
| Michael Halstead | RSU | 7,907 | — | 566,299 |
| Suresh Durgam | RSU | 7,907 | — | 566,299 |
| Mark Neumann | RSU | 7,907 | — | 566,299 |
| Michael Halstead | PSU | 8,814 | — | 631,259 |
| Suresh Durgam | PSU | 8,814 | — | 631,259 |
| Mark Neumann | PSU | 8,814 | — | 631,259 |
| Lawrence Hineline | PSU | 8,946 | — | 640,713 |
| Lawrence Hineline | Option | 9,078 | 56.73 | — |
| Michael Halstead | PSU | 9,488 | — | 679,531 |
| Suresh Durgam | PSU | 9,488 | — | 679,531 |
| Mark Neumann | PSU | 9,488 | — | 679,531 |
| Lawrence Hineline | RSU | 11,164 | — | 799,566 |
| Michael Halstead | Option | 11,944 | 56.73 | — |
| Suresh Durgam | Option | 11,944 | 56.73 | — |
| Mark Neumann | Option | 11,944 | 56.73 | — |
| Lawrence Hineline | PSU | 13,134 | — | 940,657 |
| Michael Halstead | PSU | 13,134 | — | 940,657 |
| Suresh Durgam | PSU | 13,134 | — | 940,657 |
| Mark Neumann | PSU | 13,134 | — | 940,657 |
| Michael Halstead | RSU | 14,690 | — | 1,052,098 |
| Suresh Durgam | RSU | 14,690 | — | 1,052,098 |
| Mark Neumann | RSU | 14,690 | — | 1,052,098 |
| Sharon Mates | Option | 17,824 | 36.89 | — |
| Sharon Mates | RSU | 22,590 | — | 1,617,896 |
| Sharon Mates | PSU | 24,678 | — | 1,767,438 |
| Sharon Mates | PSU | 27,108 | — | 1,941,475 |
| Sharon Mates | Option | 33,445 | 56.73 | — |
| Lawrence Hineline | RSU | 39,398 | — | 2,821,685 |
| Michael Halstead | RSU | 39,398 | — | 2,821,685 |
| Suresh Durgam | RSU | 39,398 | — | 2,821,685 |
| Mark Neumann | RSU | 39,398 | — | 2,821,685 |
| Sharon Mates | PSU | 40,712 | — | 2,915,793 |
| Sharon Mates | RSU | 41,131 | — | 2,945,802 |
| Sharon Mates | RSU | 122,137 | — | 8,747,452 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert L. Van NostrandIndependent · Lead Independent Director · Audit (Chair) | $107,639 | $99,959 | $299,985 | — | — | $507,583 |
| Joel S. MarcusIndependent · Compensation (Chair) | 73,393 | 99,959 | 299,985 | — | — | 473,337 |
| Rory B. RiggsIndependent · Audit | 70,563 | 99,959 | 299,985 | — | — | 470,507 |
| E. Rene SalasIndependent · Audit | 61,357 | 99,959 | 299,985 | — | — | 461,301 |
| Sharon MatesEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $675,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,750 |
| Stock ownership guideline | $150,000 |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $312,952 |
| Equity awards (grant-date value) | $399,836 |
| All other compensation | $0 |
| Total cost of the board | $712,788 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Intra-Cellular Therapies as a peer
Companies that benchmark against ITCI
25 companies name ITCI as a compensation peer
The list of companies that name ITCI as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
INSM Insmed IncorporatedEXEL Exelixis, Inc.RARE Ultragenyx Pharmaceutical Inc.SUPN Supernus Pharmaceuticals, Inc.SAGE Sage Therapeutics, Inc.SRPT Sarepta Therapeutics, Inc.ACAD ACADIA Pharmaceuticals Inc.FOLD Amicus Therapeutics, Inc.APLS Apellis Pharmaceuticals, Inc.BCRX BioCryst Pharmaceuticals, Inc.BPMC Blueprint Medicines CorporationFGEN FibroGen, Inc.HALO Halozyme Therapeutics, Inc.IONS Ionis Pharmaceuticals, Inc.NBIX Neurocrine Biosciences, Inc.PCRX Pacira BioSciences, Inc.PTCT PTC Therapeutics, Inc.
Peer reciprocity
The companies Intra-Cellular Therapies names as compensation peers that name it back in their own disclosed peer groups.
Insmed Incorporated (INSM)178Ultragenyx Pharmaceutical Inc. (RARE)179Sage Therapeutics, Inc. (SAGE)180ACADIA Pharmaceuticals Inc. (ACAD)181Apellis Pharmaceuticals, Inc. (APLS)182Halozyme Therapeutics, Inc. (HALO)183PTC Therapeutics, Inc. (PTCT)184
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 4 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 5 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 6 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 7 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 8 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 9 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 10 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 11 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 12 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 13 | Intra-Cellular Therapies | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 14 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 15 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 16 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 17 | Sage Therapeutics, Inc. | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 18 | FibroGen, Inc. | 2025 | Thane Wettig | 665,000 | 0 | 846,023 | 580,545 | 2,113,842 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Intra-Cellular Therapies | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| FibroGen, Inc. | 116.4% | Options 100 | not disclosed | Compensia, Inc. |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences, Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Sage Therapeutics, Inc. | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-14 | 80,788,125 | 7,537,868 | 4,087,595 | 91.47% | Passed |
| 2023 | 2023-06-23 | 74,899,928 | 5,538,593 | 33,037 | 93.11% | Passed |
| 2022 | 2022-06-09 | 68,532,689 | 12,891,962 | 65,514 | 84.17% | Passed |
| 2021 | 2021-06-21 | 59,417,585 | 3,024,206 | 124,810 | 94.97% | Passed |
| 2020 | 2020-05-27 | 50,400,532 | 713,916 | 79,361 | 98.6% | Passed |
| 2019 | 2019-06-25 | 32,961,244 | 11,184,888 | 890,112 | 74.66% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-14 | 91.47%a |
| 2023 | 2023-06-23 | 93.11%b |
| 2022 | 2022-06-09 | 84.17%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
b. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 46 : 1 |
|---|---|
| CEO total compensation | $10,086,413 |
| Median employee compensation | $217,585 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Rory B. Riggs | Director | 2024-12-31 | A | 215 | $84 | $17,957 | Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-01-31 | D | 4,730 | 127 | 600,710 | Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-01-31 | A | 11,017 | 0 | 0 | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-01-31 | A | 11,017 | 0 | 0 | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-01-31 | D | 4,729 | 127 | 600,583 | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-01-31 | D | 5,691 | 127 | 722,757 | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-01-31 | A | 11,017 | 0 | 0 | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-01-31 | A | 30,847 | 0 | 0 | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-01-31 | D | 15,233 | 127 | 1,934,591 | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-02-03 | A | 22,727 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-02-03 | A | 121,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-02-03 | A | 45,454 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-02-03 | A | 24,621 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanjeev Narula | Executive Vice President & CFO | 2025-02-03 | A | 22,727 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joel S. Marcus | Director | 2025-02-24 | A | 7,009 | 64 | 447,104 | Common | Form 4 ↗ |
| Joel S. Marcus | Director | 2025-02-24 | D | 7,009 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-01 | D | 8,742 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-01 | A | 8,742 | — | — | Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-01 | D | 3,709 | 128 | 475,494 | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-01 | D | 8,742 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-01 | D | 3,709 | 128 | 475,494 | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-01 | A | 8,742 | — | — | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-01 | A | 12,239 | — | — | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-01 | A | 34,969 | — | — | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-01 | D | 16,978 | 128 | 2,176,580 | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-01 | D | 6,261 | 128 | 802,660 | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-01 | D | 12,239 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-01 | D | 34,969 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-06 | A | 40,712 | — | — | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-06 | D | 13,133 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-06 | D | 6,718 | 131 | 881,334 | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-06 | A | 13,133 | — | — | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-06 | D | 13,133 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-06 | D | 5,572 | 131 | 730,991 | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-06 | A | 13,133 | — | — | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-06 | D | 40,712 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-06 | D | 19,848 | 131 | 2,603,859 | Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-06 | D | 13,133 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-06 | D | 5,572 | 131 | 730,991 | Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-06 | A | 13,133 | — | — | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-10 | D | 7,345 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-10 | D | 3,757 | 131 | 493,069 | Common | Form 4 ↗ |
| Michael Halstead | President | 2025-03-10 | A | 7,345 | — | — | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-10 | D | 7,345 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-10 | D | 20,566 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-10 | D | 7,345 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-10 | D | 3,116 | 131 | 408,944 | Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-03-10 | A | 7,345 | — | — | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-10 | A | 7,345 | — | — | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-10 | D | 10,129 | 131 | 1,329,330 | Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-03-10 | D | 3,116 | 131 | 408,944 | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-10 | A | 20,566 | — | — | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-26 | D | 190,000 | 0 | 0 | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-03-26 | A | 190,000 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 69,940 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 50,167 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 16,757 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 11,340 | 132 | 1,496,880 | Common | Form 4 ↗ |
| Sanjeev Narula | Executive Vice President & CFO | 2025-04-02 | D | 22,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sanjeev Narula | Executive Vice President & CFO | 2025-04-02 | D | 35,046 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 40,713 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sanjeev Narula | Executive Vice President & CFO | 2025-04-02 | D | 17,251 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 8,742 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | A | 8,742 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 13,134 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | A | 13,134 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 24,621 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 17,485 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 13,133 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 53,471 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joel S. Marcus | Director | 2025-04-02 | D | 2,951 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joel S. Marcus | Director | 2025-04-02 | D | 4,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 34,970 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 12,240 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 7,009 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 4,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 16,757 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | A | 34,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 40,712 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | A | 40,712 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 17,916 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 18,714 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 53,967 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 42,913 | 132 | 5,664,516 | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 121,212 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 138,473 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 135,399 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joel S. Marcus | Director | 2025-04-02 | D | 10,000 | 132 | 1,320,000 | Common, indirect | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | D | 8,742 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | D | 13,134 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | D | 22,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | A | 13,134 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | D | 17,485 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | D | 13,133 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | D | 52,811 | 132 | 6,971,052 | Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 2,951 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | A | 12,240 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 45,454 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 24,478 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 17,916 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 40,472 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 21,307 | 132 | 2,812,524 | Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 7,009 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 131,512 | 132 | 17,359,584 | Common | Form 4 ↗ |
| E. Rene Salas | Director | 2025-04-02 | D | 2,951 | — | — | Derivative, Class A Common | Form 4 ↗ |
| E. Rene Salas | Director | 2025-04-02 | D | 1,567 | 132 | 206,844 | Common | Form 4 ↗ |
| E. Rene Salas | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 2,951 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suresh Durgam | EVP, Chief Medical Officer | 2025-04-02 | D | 33,443 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 86,003 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | D | 17,916 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 4,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Van Nostrand | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Neumann | EVP, Chief Commercial Officer | 2025-04-02 | A | 8,742 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | A | 13,134 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| E. Rene Salas | Director | 2025-04-02 | D | 4,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| E. Rene Salas | Director | 2025-04-02 | D | 7,009 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 13,133 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Halstead | President | 2025-04-02 | D | 13,134 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 66,886 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rory B. Riggs | Director | 2025-04-02 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 945,235 | 132 | 124,771,020 | Common | Form 4 ↗ |
| Sharon Mates | Director | 2025-04-02 | D | 190,000 | 132 | 25,080,000 | Common, indirect | Form 4 ↗ |
| E. Rene Salas | Director | 2025-04-02 | D | 16,757 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joel S. Marcus | Director | 2025-04-02 | D | 48,238 | 132 | 6,367,416 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (184 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sharon Mates. DEF 14A, filed 2024-04-29. Section “Executive Compensation”. As printed: 10,086,413. View filing ↗
- Section 01, Mark Neumann. DEF 14A, filed 2024-04-29. Section “Executive Compensation”. As printed: 3,543,028. View filing ↗
- Section 01, Michael Halstead. DEF 14A, filed 2024-04-29. Section “Executive Compensation”. As printed: 3,526,233. View filing ↗
- Section 01, Suresh Durgam. DEF 14A, filed 2024-04-29. Section “Executive Compensation”. As printed: 3,511,175. View filing ↗
- Section 01, Lawrence Hineline. DEF 14A, filed 2024-04-29. Section “Executive Compensation”. As printed: 3,361,110. View filing ↗
- Section 03, Suresh Durgam PSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Suresh Durgam RSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Neumann RSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Lawrence Hineline RSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Halstead RSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sharon Mates RSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Neumann PSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Lawrence Hineline PSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Halstead PSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sharon Mates PSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2024-04-29. Section “CEO Pay Ratio”. As printed: 46 : 1. View filing ↗
- Section 08, Robert L. Van Nostrand. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 507,583. View filing ↗
- Section 08, Joel S. Marcus. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 473,337. View filing ↗
- Section 08, Rory B. Riggs. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 470,507. View filing ↗
- Section 08, E. Rene Salas. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 461,301. View filing ↗
- Section 08, Sharon Mates. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Rory B. Riggs 2024-12-31. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-01-31. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-02-03. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-02-03. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-02-03. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-02-03. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanjeev Narula 2025-02-03. Form 4, filed 2025-02-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joel S. Marcus 2025-02-24. Form 4, filed 2025-02-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joel S. Marcus 2025-02-24. Form 4, filed 2025-02-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-01. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-06. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-10. Form 4, filed 2025-03-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-26. Form 4, filed 2025-03-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-03-26. Form 4, filed 2025-03-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanjeev Narula 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanjeev Narula 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanjeev Narula 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joel S. Marcus 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joel S. Marcus 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joel S. Marcus 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rene Salas 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rene Salas 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rene Salas 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Durgam 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert L. Van Nostrand 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Neumann 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rene Salas 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rene Salas 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Halstead 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rory B. Riggs 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sharon Mates 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, E. Rene Salas 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joel S. Marcus 2025-04-02. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: 91.47% (votes for as printed: 80,788,125). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-23. Item 5.07 · say-on-pay result. As reported: 93.11% (votes for as printed: 74,899,928). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-13. Item 5.07 · say-on-pay result. As reported: 84.17% (votes for as printed: 68,532,689). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 312,952 + equity 399,836 + all other 0 = 712,788, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- PTC Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. View filing ↗
- Halozyme Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. View filing ↗
- Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Insmed Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. View filing ↗
- Blueprint Medicines Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. View filing ↗
- Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
- BioCryst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. View filing ↗
- Pacira BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Intra-Cellular Therapies (subject), Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
- Sage Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics, Inc.'s own proxy. As printed: 7,112,589. View filing ↗
- FibroGen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in FibroGen, Inc.'s own proxy. As printed: 2,113,842. View filing ↗
- Section 10a, Insmed Incorporated reciprocity. DEF 14A. Insmed Incorporated names Intra-Cellular Therapies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity. DEF 14A. Ultragenyx Pharmaceutical Inc. names Intra-Cellular Therapies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Sage Therapeutics, Inc. reciprocity. DEF 14A. Sage Therapeutics, Inc. names Intra-Cellular Therapies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ACADIA Pharmaceuticals Inc. reciprocity. DEF 14A. ACADIA Pharmaceuticals Inc. names Intra-Cellular Therapies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Apellis Pharmaceuticals, Inc. reciprocity. DEF 14A. Apellis Pharmaceuticals, Inc. names Intra-Cellular Therapies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Halozyme Therapeutics, Inc. reciprocity. DEF 14A. Halozyme Therapeutics, Inc. names Intra-Cellular Therapies in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, PTC Therapeutics, Inc. reciprocity. DEF 14A. PTC Therapeutics, Inc. names Intra-Cellular Therapies in its own disclosed peer group (read from its most recent proxy). View filing ↗